bluuebunny/crossref_metadata_2025 huggingface dataset:
Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.
Authors: Bowman Garrett , Ouf Mahmoud , Zhu Lin , Derry-Vick Heather , Dash Chiranjeev , Wang Judy Huei-yu , Kulasekaran Monika , O'Bryan James , Loffredo Christopher , He Aiwu Ruth
Published: July 2024

TPS1641

Background: Biliary tract cancer (BTC) represents 7% of gastrointestinal malignancies in the United States, with an incidence of 0.5 to 2.0 cases per 100,000 individuals. Standard care involves systemic chemotherapy, predominantly gemcitabine and cisplatin. Recent advancements in immunotherapy, as evidenced by the TOPAZ-1 trial and KN966, support the use of durvalumab, and pembrolizumab as treatment options. Genetic tumor testing identifies up to 40% of BTC patients with targetable mutations, leading to recent FDA approvals for FGFR2 inhibitors - pemigatinib, infigratinib, futibatinib, and IDH1 inhibitor ivosidenib. The emerging data on inhibitors targeting the BRAF mutation, together with HER2 amplification, underscore the importance of understanding the tumor's molecular profile. Navigating this evolving treatment landscape emphasizes an unmet need for patients to comprehend the pivotal significance of tumor molecular profiling in formulating effective and personalized treatment plans. Identifying knowledge gaps among BTC patients concerning tumor genetic testing and precision medicine, along with strategies to address these gaps, holds promise for improving the management and the outcome of patients with BTC. Methods: This is a behavioral intervention study where participants will undergo two in-person survey interviews before and after an educational intervention. The initial survey aims to establish baseline knowledge about the BTC diagnosis and treatment and ascertain preferences for various educational interventions. Patients’ knowledge gap will be determined by comparing their responses to the initial survey and medical history documented by their treating physicians. They will then be provided with a 10-minute educational video. Participants will have the flexibility to access the video multiple times. Within 6 weeks from enrollment, they will have a post-education survey to determine the effectiveness of the education intervention. Following completion of baseline surveys, collaboration with key stakeholders including medical oncology and community perspectives will be initiated to identify knowledge gaps and inform the design of an educational intervention. The study enrollment will be targeted at BTC patients receiving systemic therapy at Georgetown University Hospital, Fox Chase Cancer Center, and Hackensack Meridian Health. Ten participants are enrolled and have completed the first survey and intervention. This study is currently enrolling participants: GUIRB: STUDY00007119.
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).
Authors: Henick Brian S. , Veluswamy Rajwanth , Halmos Balazs , Labbe Kristen , Sender Naomi , Sta Ana Sarah , Chen Lanyi Nora , Punekar Salman Rafi , Singh Jasleena , Lee Matthew , Shu Catherine A. , Herzberg Benjamin , Chin Lynda , Velcheti Vamsidhar
Published: July 2024

TPS1642

Background: ICI have changed the treatment landscape of NSCLC, with many now FDA approved in not just advanced, but even early-stage disease. With the increase in ICI use, the incidence of immune-related adverse effects (irAEs) has also risen, occurring in up to 16% of ICI-treated patients. Prompt recognition and timely management are necessary to avert potential poor outcomes from direct toxicity and/or early treatment discontinuation. However, existing barriers to access care that disproportionately impact racial and ethnic minority patients may amplify challenges in early, effective management of irAEs. Using technology-enabled health interventions in a culturally competent manner can improve access to health care resources and reduce health disparities. These platforms need to be optimized at the technology and health literacy level of underserved minority communities and adapted to meet the community's needs. Methods: We have designed a multi-center phase IV clinical trial to 1) assess factors related to suboptimal and optimal use of the ApricityCARE, a virtual first-response clinical support (or coverage) to provide 24/7 symptom monitoring and side effect management and 2) determine the impact of the program on ICI toxicity management for NSCLC patients receiving ICIs in a highly diverse community. Eligible patients are those with a confirmed diagnosis of NSCLC who self-identify as a member of an ethnic minority or underserved population, prescribed for any treatment regimen that includes an ICI. The study entails a 50-patient run-in phase with two focus group discussions, stratified on a Likert-type scale based on the frequency of utilization, to determine factors impacting usability of the ApricityCare program. This data will inform optimal implementation of ApricityCare for the randomized phase of the study, where 230 patients will be assigned 1:1 to use of ApricityCare versus standard of care. The run-in phase of the study is currently accruing at Columbia University, and is planned to open at NYU, Mount Sinai, and Montefiore (NCT05812274). Clinical trial information: NCT05812274 .
GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.
Authors: Zhou Jian , Cheng Ann-Lii , Ikeda Masafumi , Lim Ho Yeong , Akce Mehmet , Qin Shukui , Oh Do-Youn , Chan Stephen Lam , Xiang Jinfeng , Qu Xiao , Xie Ruifan , Yang Ming , Kumar Rakesh , Abou-Alfa Ghassan K.
Published: July 2024

TPS4187

Background: Although targeted therapies and immuno-oncology (IO)-based regimens have improved overall survival (OS) in advanced hepatobiliary carcinomas, long-term survival rates remain unsatisfactory. Early-phase studies have demonstrated the efficacy of volrustomig (volru; anti-PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody [mAb]) in patients (pts) with non-small-cell lung cancer (NSCLC) and renal cell carcinoma, and of rilvegostomig (rilve; anti-PD-1/TIGIT bispecific humanized IgG1 mAb) in pts with NSCLC, along with manageable safety profiles. GEMINI-Hepatobiliary (NCT05775159) is a phase 2, open-label, multidrug, multicenter, master protocol study designed to evaluate the preliminary efficacy and safety of novel IO bispecific mAbs as monotherapy or in combination with standard of care anticancer agents in pts with advanced hepatocellular carcinoma (HCC) and biliary tract cancer (BTC). Methods: The GEMINI-Hepatobiliary platform design permits separate independent substudies (Table). Substudy 1 includes treatment-naïve adults (≥18 years) with histologically confirmed advanced HCC not eligible for locoregional therapy, Barcelona Clinic Liver Cancer Stage B/C, Child-Pugh class A 5–6, and an ECOG performance status (PS) of 0–1. Pts will be treated with volru as monotherapy or in combination with bevacizumab or lenvatinib. Primary endpoints for Substudy 1 are safety and objective response rate (ORR) per RECIST v1.1 by investigator’s assessment. Substudy 2 includes treatment-naïve adults with locally advanced or metastatic, histologically confirmed BTC and an ECOG PS of 0–1. Pts will be treated with gemcitabine + cisplatin with either rilve or volru. Primary endpoints for Substudy 2 are safety and progression-free survival (PFS) per RECIST v1.1 by investigator’s assessment. Secondary endpoints for both substudies include duration of response, disease control rate, ORR, PFS, OS, pharmacokinetics, and immunogenicity. While there are no formal statistical comparisons or hypothesis testing, sample sizes were selected to provide adequate precision for the primary endpoints. The study is currently recruiting at sites in the US, Asia, and Europe. GEMINI-Hepatobiliary master protocol design. Clinical trial information: NCT05775159 . [Table: see text]
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM).
Authors: Tsang Erica S , Shi Qian , Olive Kenneth P. , Collisson Eric Andrew , Dixon Jesse G. , Cusnir Mike , Winograd Rafael , Botta Gregory P. , Wadlow Raymond Couric , Shergill Ardaman , Meyerhardt Jeffrey A. , O'Reilly Eileen M. , Ko Andrew H.
Published: July 2024

TPS4205

Background: Multiple lines of evidence support the use of platinum-based chemotherapy for patients with homologous recombination deficiency-associated pancreatic adenocarcinoma (HRD PDAC; 15-20%). However, the impact of the specific platinum agent used remains uncertain. Mechanistically, oxaliplatin and cisplatin act distinctly on cancer cells, reflected in disparate toxicity profiles and target disease indications; furthermore, preclinical studies have shown that BRCA2-deficient cell lines and mice demonstrate significantly greater sensitivity to cisplatin compared to oxaliplatin. While oxaliplatin, part of the FOLFIRINOX regimen, represents the most commonly used platinum analogue for PDAC, clinical data shows that cisplatin (in combination with gemcitabine) can produce robust response rates (~70%) specifically in patients with germline BRCA/PALB2-mutated metastatic PDAC. We therefore designed a randomized clinical trial (PLATINUM) through the Alliance for Clinical Trials in Oncology cooperative group to assess the optimal chemotherapy regimen in patients with HRD-associated metastatic PDAC following front-line FOLFIRINOX and to test the hypothesis that a platinum switch strategy will be beneficial. Methods: The study consists of a seamless phase II/III design, with the primary endpoint of the phase III component being overall survival. Eligible patients will have metastatic PDAC, a confirmed pathogenic BRCA1/2 or PALB2 mutation (somatic or germline), and demonstrated disease progression on front-line FOLFIRINOX, with or without subsequent PARP inhibitor maintenance. Patients will be randomized 1:1 to receive (1) the de facto standard of gemcitabine plus nab-paclitaxel; or (2) the experimental 3-drug combination of gemcitabine, nab-paclitaxel, and cisplatin (NABPLAGEM), which has been previously studied in non-biomarker-selected patients with advanced biliary tract cancer (SWOG1815) and metastatic PDAC. Both treatment arms will use a once every other week dosing schedule. A total of 100 patients will be enrolled, which provides 90% power to detect an effect size of hazard ratio 0.5 (median OS of 18 vs 9 months) at a one-sided alpha of 0.05. Reports containing efficacy, adverse events, and administrative information will be provided to the Alliance DSMB every 6 months. Planned correlatives include ctDNA analysis for BRCA reversion mutations in all patients, as well as whole genome and transcriptome sequencing in an optional biopsy cohort. This study was activated in December 2023. Clinical trial information: NCT06115499 .
A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
Authors: Fountzilas Christos , Ko Andrew H. , Borazanci Erkut Hasan , D'Olimpio James Thomas , Hecht J. Randolph , Tang Shou-Ching , Shields Anthony F. , Salkeni Mohamad Adham , Michelson Glenn , Cho Gene , Liganor Lorna , Cho Sangsook Ahn , Walker Evan Justin
Published: July 2024

TPS4206

Background: Front-line chemotherapy for patients (pts) with advanced or mPDAC typically consists of mFOLFIRINOX or gemcitabine/nab-paclitaxel given until disease progression or intolerable toxicity. For pts with durable disease control on front-line treatment, maintenance therapy that can effectively delay disease progression while preserving quality of life with minimal cumulative toxicity is highly desirable. Ivaltinostat (ival) is a pan-histone deacetylase inhibitor that increases histone acetylation, suppresses PDAC cell proliferation, and promotes apoptosis in PDAC cell lines. Preclinical data demonstrated synergy with 5-FU/cape in mouse models. RP2D of the Phase 1b combination study of ival and cape in advanced pancreatic cancer was ival 250mg/m2 IV on days 1 and 8 with cape 1000mg/m2 po days 1-14 of a 21-day cycle. Both ival and cape treatment-related AEs >15% were fatigue, nausea, diarrhea, and decreased appetite. Palmar-plantar erythrodysaesthesia syndrome was also commonly observed; all events were attributed to cape. PK and PD demonstrated dose proportionality. Overall and progression-free survival (PFS) were immature, but 70% of pts who enrolled with measurable disease had stable disease as best response. Several pts remained on study with the longest duration of response about 10 months, as of the data cut off for ASCO GI 2024. Based on this data, a randomized phase 2 study is being conducted comparing the combination of ival and cape versus cape alone in the maintenance setting for pts with mPDAC after first line FOLFIRINOX, mFOLFIRINOX or NALFIRINOX therapy. Methods: Key eligibility criteria for the randomized Phase 2 study include: mPDAC; no evidence of disease progression following at least 16 weeks of front-line FOLFIRINOX or NALIRIFOX at full or modified doses; ECOG PS 0-1; and no known germline BRCA1/2 mutation. A total of 52 pts will be randomized 1:1 to receive cape with or without ival until disease progression, with tumor assessments occurring at 6-week intervals. The primary endpoint is investigator-adjudicated PFS, and the primary analysis will compare PFS distributions in the ival/cape and cape alone arms using a one-sided log rank test with an alpha=0.10. The assumed 6-mo PFS rates are 35% (cape), based on historic data, and 60% (ival/cape), corresponding to an HR of 0.487. Enrollment in the phase 2 study began in January 2024 across multiple sites in the US. Accrual is anticipated to complete 4Q2024. Clinical trial information: NCT05249101 .
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.
Authors: Manji Gulam Abbas , May Michael S. , Chalabi Morteza , Pellicciotta Ilenia , Sta Ana Sarah , Sender Naomi , Pan Samuel M , Ross Isabelle , Wang Shikun , Izar Benjamin , Wu Linda , Labadie Brian William , Bates Susan Elaine , Shi Qian , Raufi Alexander G
Published: July 2024

TPS4208

Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) carries a 5-year relative survival of 3%. Immune checkpoint inhibitors have thus far failed to improve outcomes due to an immunosuppressive tumor microenvironment (TME). Signaling through the C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis results in exclusion of anti-tumor immune cells in mouse PDAC models. Longitudinal survival studies testing combinations of CXCR4i, aPD-1, and gemcitabine in the KPC mouse model of PDAC demonstrated a survival benefit with the combination of all three agents. Results from a multicenter, investigator-initiated, single arm pilot study evaluating the preliminary safety and efficacy ofMotixafortide (CXCR4i), Cemiplimab (aPD1), Gemcitabine, and Nab-paclitaxel (MCGN) in 11 patients with treatment-naïve mPDAC were recently presented. Seven patients (64%) achieved a partial response, including 6 confirmed partial responses, and 10 patients (91%) had disease control, compared to historic partial response and disease control rates of 23% and 48%, respectively, with gemcitabine and nab-paclitaxel (GN). Preliminary median progression-free survival (PFS) was 9.6 months compared to historic median PFS of 5.5 months with GN. Analysis of paired pre- and on-treatment biopsy samples from demonstrated an increase in CD8+ T-cell density in tumors from all 11 patients treated with MCGN (p=0.007). Based on these promising results, the protocol was amended from a single arm expansion totaling 40 patients to a randomized phase 2 study. Methods: This is an open-label, multicenter, investigator-initiated phase 2 clinical trial. Patients are randomized 2:1 to receive MCGN or GNalone (N=108). The primary endpoint is progression free survival. The study has 80% power to detect an improvement in PFS from 6 to 9.2 months (HR 0.65) with a one-sided alpha of 0.20. One interim analysis for futility is planned when 50% of the PFS events are observed. Secondary objectives include response rate, disease control rate, duration of clinical benefit and overall survival. Patients will undergo optional paired biopsies which will be analyzed in conjunction with samples collected from the phase I pilot study. Exploratory studies include interrogation of the TME using quantitative multiplex immunofluorescence and single-cell RNA sequencing. The randomized phase 2 trial is open to enrollment and one patient has been randomized as of 1/29/2024. Clinical trial information: NCT04543071 .
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).
Authors: Jiang Kuirong , Tu Min , Xu Dong , Lv Nan , Wang Qianqian
Published: July 2024

TPS4213

Background: Locally advanced pancreatic adenocarcinoma (LAPC) constitutes a significant proportion of pancreatic cancer, which ranks among the most lethal malignancies globally. Treatment options specifically tailored for LAPC patients (pts) are scarce, and chemotherapy alone yields limited efficacy. Various studies have provided supportive evidence for the synergistic effects of combining immunotherapy with chemotherapy in the context of pancreatic cancer. Cadonilimab, a novel recombinant humanized bispecific antibody, holds the capability to concurrently inhibit PD-1 and CTLA-4 pathways, thereby restoring T-cell immune response to the tumor. This study aims to assess the efficacy and safety of combining cadonilimab with modified FOLFIRINOX for the treatment of LAPC. Methods: This ongoing phase II trial is enrolling pts with histologically or cytologically confirmed unresectable LAPC who have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1 and have not previously received systemic anti-tumor therapy. Eligible pts will be administered cadonilimab (6mg/kg, intravenous drip, Day 1, every 2 weeks) plus mFOLFIRINOX (oxaliplatin 85mg/m2, Day 2 + leucovorin 400mg/ m2, Day 2 + irinotecan 150mg/ m2, Day 2 + 5-fluorouracil 2,400mg/ m2, continuous infusion for 46 hours) for a total of 4 cycles (8 weeks). After the completion of every 4 treatment cycles, pts will undergo imaging examinations of tumor lesions. Pts will receive treatment continuously until surgical resection, disease progression, intolerable toxic reactions, initiation of new anticancer drug treatments, withdrawal from the study, death, or loss of follow-up. Following the 12th cycle of treatment, maintenance treatment will consist of capecitabine or S-1 in combination with cadonilimab. The primary endpoint of this study was the R0/R1 resection rate. The main secondary endpoints include the objective response rate (ORR) per RECIST 1.1, progression-free survival (PFS), overall survival (OS), and safety assessments. Additionally, pts will undergo peripheral blood next-generation sequencing (NGS) panel analysis before and after treatment to investigate the correlation between circulating tumor DNA (ctDNA) changes, surgical decisions, and prognosis. Enrollment is ongoing. Clinical trial information: NCT06153368 .
A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC).
Authors: Jazaeri Amir A. , Grisham Rachel N. , Gaillard Stephanie , How Jeffrey Andrew , Hazard Sebastien , Musso Lauren , Kyi Chrisann
Published: July 2024

TPS5633

Background: IMNN-001, an interleukin-12 (IL-12) DNA plasmid formulated with a DNA carrier, polyethyleneglycol-polyethyleneimine cholesterol lipopolymer, has been shown to exhibit a favorable benefit/risk ratio when administered intraperitoneally (IP), in combination with intravenous platinum-taxane chemotherapy, up to doses of 100 mg/m2 in women with advanced EOC in earlier Phase I & II studies. The 201-21-202 study (NCT05739981) is a multi-center, randomized, open-label phase I/II study which hypothesizes the addition of IMNN-001 to neoadjuvant & adjuvant carboplatin-paclitaxel and bevacizumab (chemo + BEV) reduces the risk of histologically documented minimal residual disease (MRD) as determined by SLL by 50%. Methods: Patients with newly diagnosed stage III and IV high grade serous EOC who are candidates for NACT will be enrolled into the trial. Initial safety lead-in will evaluate at least 6 patients randomized to the experimental arm. Upon confirmation of safety by the DSMB, a target of ~50 patients will be randomized 1:1 to receive either chemo + BEV with or without IMNN-001. Patients receive at least 4 cycles of NACT followed by interval cytoreductive surgery (ICS), and 3 additional adjuvant cycles of study treatments will be administered. BEV will be included with each cycle except cycle 1, the last cycle of NACT immediately preceding ICS, and the first cycle of adjuvant chemotherapy. In the experimental arm, IMNN-001 will be administered on C1D15 and continue weekly though the last cycle of adjuvant therapy. Following adjuvant therapy, all patients will undergo SLL with peritoneal washing and multiple biopsies. Pathologic detection of residual tumor in any biopsies or peritoneal cytology constitutes presence of MRD. All patients will receive maintenance therapy with Olaparib + BEV, IMNN-001 + BEV, or BEV alone based on their homologous recombination deficiency status and treatment randomization. Translational:All subjects will undergo biospecimen collection and organoid preparation prior to treatment, at the time of ICS and SLL for comprehensive longitudinal genomic, circulating tumor DNA, immune, and microbiome profiling. Subjects in the experimental arm will also undergo peritoneal lavage and collection of fluid and cells for assessment of the peritoneal tumor environment. Endpoints: The primary endpoint is the rate of MRD at SLL. Secondary endpoints include progression-free survival, overall survival, objective response rate, chemotherapy response score, surgical response, and serologic response. All patients will be evaluated for safety. Status: The study is actively enrolling and is in the safety lead-in portion. We plan to enlist approximately 4 sites in USA. Clinical trial information: NCT05739981 .
Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).
Authors: Erickson Britt Kristina , Enserro Danielle , Lankes Heather A. , Dockery Lauren E. , ghamande sharad A. , Oliver Matthew T. , Gressel Gregory M. , Castellano Tara , Ratner Elena , Deery Amy , Bishop Erin , Bradford Leslie Siriya , Thomes Pepin Jessica , Burton Elizabeth , Blank Stephanie V. , Santin Alessandro , Havrilesky Laura J , Aghajanian Carol , Nickles Fader Amanda , Powell Matthew A.
Published: July 2024

TPS5641

Background: Uterine serous carcinoma and uterine carcinosarcoma are rare, high-risk uterine cancer subtypes that overexpress HER2 in up to 40% and 10% of cases, respectively. Phase II data demonstrated a benefit in adding trastuzumab in HER2 positive advanced and recurrent uterine serous carcinoma. Dual anti-HER2 therapy has the potential for further improvement in survival. Methods: This is a non-blinded, three-arm randomized phase II/III study. The primary objective is to evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or a fixed dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive uterine serous carcinoma or carcinosarcoma. The primary outcome of the phase II component is PFS. Depending on the phase II results, the study will progress to a phase III study of either two or three study arms. Patients in the control arm (Arm 1) receive carboplatin and paclitaxel every 3 weeks for 6 cycles. Patients on Arm 2 receive carboplatin and paclitaxel with trastuzumab and hyaluronidase-oysk every 3 weeks for 6 cycles plus one year of maintenance trastuzumab and hyaluronidase-oysk. Patients enrolled on Arm 3 receive carboplatin and paclitaxel with trastuzumab, pertuzumab, and hyaluronidase-zzxf every 3 weeks for 6 cycles plus one year of maintenance trastuzumab, pertuzumab, and hyaluronidase-zzxf . Those with an ongoing partial response may continue maintenance therapy for up to three years. Patients are eligible if they are diagnosed with chemo-naïve, non-recurrent stage IA-IVB myoinvasive uterine serous or carcinosarcoma. All tumors must be HER2 positive as defined by the ASCO/CAP Breast Cancer 2018 guidelines (testing performed locally). Tumors may also be HER2 positive based on next generation sequencing testing. Patients may have measurable, non-measurable, or no measurable disease and may have a plan for vaginal brachytherapy . Key exclusion criteria include severe heart disease or interstitial lung disease. The phase II portion of this study is open and enrolling. Clinical trial information: NCT05256225 .
In Search of Joy and Meaning in Modern Medicine
Authors: Tendulkar Rahul D.
Published: July 2024

Inspired by Simone's maxims, a physician shares their search for restoring joy and meaning in modern medicine.
Can Narratoscepticism Be a Valid Alternative? A Critique of Strawson’s Episodicity Argument
Authors: Lukić Vladimir
Published: July 2024

This paper argues against Galen Strawson’s criticism of the narrativist identity thesis. Strawson points out that the narrativist thesis fails to portray those with an episodic perception of themselves. I claim that episodicity is rather problematic and that we should question the validity of this notion. The first step in this goal is to decipher Strawson’s basis of the self which is an amalgam between the cultural and social and is perceived differently by different people. Afterwards, I will try to use the claims derived from Strawson’s basis and apply the critique of his method. I pose a question about the relationship between episodic and diachronic and, ultimately, argue that both culturally and biologically, assuming the diachronic aspect of the self is necessary, apart from the very small number of cases. In this sense, the main conclusion is that Strawson’s thesis is limiting but does not pose a valid alternative to the narrativist identity thesis.
The Nature of Historical Research and Scientometric Methodology
Authors: Gevorgyan Ashot , Mosinyan Davit
Published: July 2024

Historiography regularly encounters a crisis. This is mainly due to methodological reasons. History is not a representation of the past based on some archival materials because, firstly, the past is not available, secondly, the past, and therefore the present and the future, cannot be thought anew, and the historical research will not find new facts. New methods are needed to rethink the idea of the past. Recently, indicators of the development of science are in academic journals. Therefore, their analysis will allow through comparison to highlight the lacks of the historiography’s current state and identify the perspectives of their correction.
Grušovnik, Tomaž, Reingard Spannring, and Karen Lykke Syse, eds. Environmental and Animal Abuse Denial: Averting Our Gaze. Lanham, MD: Lexington Books, 2021
Authors: Protopapadaki Vicky
Published: July 2024

Environmental and Animal Abuse Denial: Averting Our Gaze edited by Tomaž Grušovnik, Reingard Spannring, and Karen Lykke Syse, stands as a groundbreaking work that delves into the intricate phenomenon of denialism, a critical barrier in addressing ecological crises and advancing animal rights. Through its compelling interdisciplinary lens, the book dissects the psychological, sociocultural, and political underpinnings of denial, challenging entrenched anthropocentric views. This review provides a critical analysis of the book and highlights its pivotal role in bridging theoretical ethics with real-world environmental and animal welfare challenges. The editors’ adept selection of contributions guides readers through a thought-provoking journey in denialism, encompassing personal introspection, societal critique, and a scrutinizing look at economic, political, and legal frameworks. Despite its primarily Western-centric perspective, the book is essential in advocating for a broader, more inclusive global dialogue in future research. The book emerges not just as an academic text but as an urgent call to action, resonating with scholars, policymakers, and activists. In essence, this work emphasizes the necessity for a transformative shift in how we perceive and interact with the natural world and its non-human inhabitants.
Αποφρακτικά νοσήματα πνευμόνων, παράγοντες κινδύνου και συννοσηρότητες τους στον ελληνικό πληθυσμό
Authors: Γαγγάδη Μαρία
Published: July 2024

Εισαγωγή: Υπάρχει έλλειψη δεδομένων για την επιδημιολογία του Αποφρακτικού Λειτουργικού Συνδρόμου (ΑΛΣ) στον ενήλικο πληθυσμό της Ελλάδας. Η μελέτη αυτή κατέγραψε τον επιπολασμό του ΑΛΣ, της Χρόνιας Αποφρακτικής Πνευμονοπάθειας (ΧΑΠ) και του Βρογχικού Άσθματος (ΒΑ), χρησιμοποιώντας την Εθνική Μελέτη Νοσηρότητας και Παραγόντων Κινδύνου (ΕΜΕΝΟ). Εξετάστηκε επίσης η συσχέτισή τους με παράγοντες κινδύνου, συμπτώματα και συννοσηρότητες σε άτομα ≥18 ετών. Μέθοδοι: Με βάση την απογραφή του 2011, η ΕΜΕΝΟ, με συγχρηματοδότηση από το Ευρωπαϊκό Κοινωνικό Ταμείο και από εθνικούς πόρους, εφάρμοσε πολυσταδιακή στρωματοποίηση κατά συστάδες με τυχαία επιλογή του δείγματος σε διάφορες περιοχές της Ελλάδας (2013-2016). Εκπαιδευμένοι ερευνητές πραγματοποίησαν κατ' οίκον επισκέψεις, όπου διενεργήθηκαν ανθρωπομετρικές μετρήσεις, εξετάσεις αίματος και σπιρομέτρηση, και συλλέχθηκαν πληροφορίες μέσω ερωτηματολογίων. Ορισμοί: ΑΛΣ (FEV1/FVC<0,75), ΧΑΠ (ηλικία ≥30, FEV1/FVC<0,7 ή <LLN, και αρνητική αυτοαναφορά για ΒΑ), ΒΑ (θετική αυτοαναφορά διάγνωσης από γιατρό). Εφαρμόστηκαν δειγματοληπτικά βάρη και στατιστικά μοντέλα.Αποτελέσματα: Από τους 6006 συμμετέχοντες, 2870 είχαν αποδεκτή σπιρομέτρηση για το ΑΛΣ. Ο επιπολασμός του ΑΛΣ, ΧΑΠ (FR), ΧΑΠ (LLN) και ΒΑ ήταν 19,5%, 8,29%, 5,15% και 5,89% αντίστοιχα. Ο επιπολασμός του ΑΛΣ και της ΧΑΠ ήταν υψηλότερος στους άνδρες (p<0,001), ενώ δεν υπήρχε διαφορά φύλου για το ΒΑ. Η ΧΑΠ αυξανόταν σημαντικά με την ηλικία (FR και FR+/LLN-), ενώ το LLN εντόπιζε νεότερους ασθενείς. Η ΧΑΠ ήταν πιο συχνή στους καπνιστές (p<0,001). Τα αναπνευστικά συμπτώματα συσχετίζονταν με υψηλότερο κίνδυνο ΧΑΠ (p<0,01), ενώ τα άτομα με καρδιαγγειακές συννοσηρότητες είχαν υψηλότερα ποσοστά ΧΑΠ (FR) στη μονοπαραγοντική ανάλυση αλλά όχι στα πολυπαραγοντικά μοντέλα. Το ΒΑ είχε υψηλό επιπολασμό στα άτομα με συμπτώματα που σχετίζονται με το ΒΑ και συγκεκριμένα 1) 64,3% στην κρίση άσθματος, 2) 24,1% στη νυχτερινή αφύπνιση από κρίση δύσπνοιας, 3) 25% στην κρίση δύσπνοιας οποιαδήποτε ώρα της ημέρας και 4) 20,9% στο συριγμό. Παρομοίως, ο σχετικός λόγος ύπαρξης ΒΑ στα άτομα με αυτά τα τέσσερα συμπτώματα ήταν σημαντικά (p<0,001) υψηλός (OR: 47,16, 6,59, 7,87, 8,23 αντίστοιχα). Επίσης, παρατηρήθηκε αυξημένη πιθανότητα διάγνωσης ΒΑ σε όσους είχαν αποφρακτική σπιρομέτρηση. Οι συννοσηρότητες ήταν συχνές στο ΒΑ (p<0,01). Συμπέρασμα: Η διάγνωση ΧΑΠ με FR υπερδιαγιγνώσκει ηλικιωμένους λόγω φυσιολογικής γήρανσης, ενώ το LLN εντοπίζει πρώιμα την απόφραξη σε νεότερους. Τα υψηλά ποσοστά ΒΑ σε άτομα με αναπνευστικά συμπτώματα υποδεικνύουν κακό έλεγχο της νόσου στην Ελλάδα, με συννοσηρότητες που επιδεινώνουν την κατάσταση.
Ανίχνευση και κλινική αξιολόγηση βιοδεικτών μεθυλίωσης DNA στο πλάσμα ασθενών με πρώιμο και μεταστατικό καρκίνο του παχέος εντέρου
Authors: Βαγιωνάς Αναστάσιος
Published: July 2024

Η επιγενετική σίγαση ογκοκατασταλτικών γονιδίων και γονιδίων συνδεόμενων με τον καρκίνο συμβάλλει στην ανάπτυξη πολλών νεοπλασματικών ασθενειών. Στον καρκίνο του μαστού η μεθυλίωση φαίνεται ότι συμβαίνει πρώιμα στη διαδικασία της καρκινογένεσης και η ανίχνευσή της αποτελεί έναν πολλά υποσχόμενο δείκτη για την έγκαιρη διάγνωση του καρκίνου, την πρόγνωση και το σχεδιασμό νέων θεραπευτικών στρατηγικών. Σκοπός της παρούσας διδακτορικής διατριβής ήταν η ανίχνευση της μεθυλίωσης τρίων ογκοκατασταλτικών γονιδίων, SOX17, WNT5a και WIF1, στο cfDNA ασθενών με πρώιμο και μεταστατικό καρκίνο του παχέος εντέρου και η εκτίμηση της πιθανής τους προγνωστικής αξίας. Η μεθυλίωση των γονιδίων SOX17, WNT5a και WIF1 ανιχνεύθηκε και στις δύο ομάδες των ασθενών δηλαδή τόσο στον πρώιμο όσο και στον μεταστατικό καρκίνο του παχέος εντέρου, ενώ ήταν μηδενική στην ομάδα ελέγχου. Το γονίδιο SOX17 ανιχνεύθηκε στο cfDNA ασθενών με πρώιμη νόσο σε χαμηλότερα επίπεδα σε σχέση με τους μεταστατικούς ασθενείς και συνδέθηκε με μειωμένη ολική επιβίωση μόνο στους ασθενείς με μετάσταση. Η μεθυλίωση του γονιδίου WNT5a αυξανεί προοδευτικά με την εξέλιξη της νόσου και φαίνεται να αποτελεί δείκτη κακής πρόγνωσης τόσο στους ασθενείς με πρώιμη νόσο όσο και στους ασθενείς με μετάσταση. Η ταυτόχρονη μεθυλίωση των δύο αυτών γονιδίων επιβεβαιώνει την πιθανή προγνωστική τους αξία. Τέλος, γίνεται αντιληπτό να υπάρχει κάποια συσχέτιση μεταξύ της μεθυλίωσης των παραπάνω γονιδίων με την ανταπόκριση ή όχι στην χημειοθεραπεία. Επίσης το γονίδιο WIF1 εμφάνισε μεγαλύτερη συχνότητα μεθυλίωσης στους ασθενείς με πρώιμο καρκίνο του παχέως εντέρου σε σχέση με τους ασθενείς των μεταστατικών δειγμάτων και αντιστοίχως παρατηρήθηκε συσχέτισή του μεταξύ της ανταπόκρισης στη θεραπεία και της μη μεθυλίωσης του γονιδίου. Τα παραπάνω αποτελέσματα φαίνεται να παρέχουν προγνωστική πληροφορία, ωστόσο, η μεθυλίωση του κάθε γονιδίου πρέπει να αξιολογηθεί περαιτέρω ως υποσχόμενος προγνωστικός βιοδείκτης, σε μεγαλύτερο αριθμό ασθενών, σε συνάρτηση με την κλινική έκβαση και την ολική επιβίωση.
Διερεύνηση της αποτελεσματικότητας των τηλεφωνικών οδηγιών στην εκτέλεση της καρδιοπνευμονικής αναζωογόνησης
Authors: Χαραλαμπόπουλος Μάριος
Published: July 2024

Εισαγωγή: Η Καρδιοπνευμονική αναζωογόνηση, εάν και αποτελεί μια σωτήρια διαδικασία, εφαρμόζεται μόνο στο 30% των περιπτώσεων καρδιακής ανακοπής ως αποτέλεσμα πολλών παραγόντων, όπως η έλλειψη γνώσεων, ο φόβος πρόκλησης περαιτέρω βλάβης. Λόγω της σπουδαιότητας της άμεσης εφαρμογής ΚΑΡΠΑ για τη διατήρηση του ασθενούς στη ζωή, ορισμένα Εθνικά Κέντρα Πρώτων Βοηθειών σε όλο τον κόσμο παρέχουν τις απαραίτητες οδηγίες στον πιθανό διασώστη μέσω τηλεφώνου ώστε να καλύψουν το οποιοδήποτε εμπόδιο και δυσκολία (Τηλεπικοινωνιακή ΚΑΡΠΑ - TCPR).ΣκοπόςΣκοπός της μελέτης αποτέλεσε η διερεύνηση της αποτελεσματικότητας των τηλεφωνικών οδηγιών στην εκτέλεση της Καρδιοπνευμονικής Αναζωογόνησης. Μεθοδολογία: Πρόκειται για συγχρονική μελέτη ατόμων τα οποία κλήθηκαν να εφαρμόσουν Καρδιοπνευμονική Αναζωογόνηση (ΚΑΡΠΑ), μόνο με θωρακικές συμπιέσεις, ακολουθώντας τηλεφωνικές οδηγίες ανταποκρινόμενοι σε σενάριο προσομοίωσης περιστατικού καρδιακής ανακοπής. Πριν και μετά τη συμμετοχή τους, συμπληρώθηκαν ειδικά ερωτηματολόγια μέτρησης γνώμης και γνώσεων σχετικά με την ΚΑΡΠΑ. Κατά τη διάρκεια της εφαρμογής ΚΑΡΠΑ, ο ερευνητής από διαφορετικό χώρο, απηύθυνε τις οδηγίες ενώ υπήρχε καταγραφή της προσομοίωσης με οπτικοακουστικά μέσα. Για την ΚΑΡΠΑ χρησιμοποιήθηκε ειδικό εκπαιδευτικό πρόπλασμα με δυνατότητα καταγραφής των ποιοτικών χαρακτηριστικών. Για την ανάλυση των αποτελεσμάτων χρησιμοποιήθηκε το στατιστικό πακέτο SPSS ver.24. Ως επίπεδο σημαντικότητας ορίστηκε το p<0.05. Αποτελέσματα: Το δείγμα αποτέλεσαν 151 άτομα με μέση ηλικία τα 38. Το 58,9% (n=89) των συμμετεχόντων ήταν γυναίκες, ενώ το 41,1% (n=62) άνδρες. Το μεγαλύτερο ποσοστό των ερωτηθέντων (83,4%, n=126) γνώριζε τι είναι η Καρδιοπνευμονική Αναζωογόνηση (ΚΑΡΠΑ) ενώ πολύ μικρότερο ποσοστό (16,6%, n=25) δεν γνώριζε. Από τα 151 άτομα, τα 115 (76,2%) δεν είχαν προηγούμενη εκπαίδευση στη ΚΑΡΠΑ. Η μέση τιμή της συνολικής βαθμολογίας απόδοσης υπολογίστηκε 7,99 ενώ ο μέσος χρόνος μεταξύ αποδοχής κλήσης και 1ης συμπίεσης είναι 39,39 δευτερόλεπτα. Ακόμη, ο μέσος αριθμός συμπιέσεων είναι 71,77 συμπιέσεις ενώ ο συνολικός μέσος αριθμός συμπιέσεων είναι 191,05. Το επάγγελμα, οι συμπιέσεις και ο συνολικός αριθμός συμπιέσεων συσχετίστηκαν στατιστικά σημαντικά με την Συνολική βαθμολογία απόδοσης των συμμετεχόντων (p=0,01, p<0,001 και p=0,004 αντίστοιχα). Συμπεράσματα: Οι τηλεφωνικές οδηγίες φαίνεται να βοηθούν στη παροχή αποτελεσματικής ΚΑΡΠΑ, να είναι εύκολα κατανοητές και εφαρμόσιμες ενώ η συνολική διαδικασία περιεγράφηκε ως εύκολη. Οι συμμετέχοντες συνολικά βίωσαν άγχος ποσοστό μεγαλύτερο των μισών. Το επάγγελμα, οι συμπιέσεις και ο συνολικός αριθμός συμπιέσεων συσχετίστηκαν στατιστικά σημαντικά με την Συνολική βαθμολογία απόδοσης των συμμετεχόντων.
Surplus of Meaning or Suspending Philology? Some Reflections on the Philological Ramification of the Classical Qurʾān Commentary
Authors: Palanci Merve
Published: July 2024

This study examines the philological data criteria used for exploring the genuine meanings and denominators of Arabic verbatim of the Qurʾān by Muslim exegetes of the classical period, with a special focus on the philological ramification of the commentary of dhālika l-kitāb pattern in Q 2:2.
Having attained the status of a corpus (kitāb) in the aftermath of a very long-phased oral tradition, the Qurʾān’s textus receptus reflects both portrayals of verbality and scriptural traits embedded in its Arabic verbatim information yielded by the compilation process. The Qurʾān, representing a junction spot for oral and written traditions in Arab culture, is known to be molded according to the Arabic language register and also formalized the language’s post facto grammar. In this vein, the Qurʾānic text bears a reflexive affiliation with its pertinent language. This article argues that the lingual reciprocity between the Qurʾānic text and its language underwent a critical suspension through commentaries when the case was Qurʾān’s al-kitāb. In this article, the first layer of the data reflects the historical background of the term kitāb. Then, it construes the word within Qurʾān’s cross-references. It exemplifies commentaries on the dhālika l-kitāb pattern, circumventing philological evidence. After elucidating different grounds leading to philological ramification, I argue that a philological inference from the Qurʾān nests in its fullest sense only when the commentator credits historical data and cross-references within the Qurʾānic content.
Między pragmatyzmem a dogmatyzmem. W kierunku rozłamu w Organizacji Ukraińskich Nacjonalistów (1929–1935)
Authors: Gibiec Magdalena
Published: July 2024

Celem artykułu jest uzupełnienie wiedzy na temat genezy rozłamu w Organizacji Ukraińskich Nacjonalistów w 1940 r. na OUN-M i OUN-B. Analizie poddałam pierwszy okres jej działalności od powstania w 1929 r. do rozpoczęcia procesu sądowego w sprawie zabójstwa ministra Bronisława Pierackiego, którego konsekwencją było skazanie Stepana Bandery na dożywotnie więzienie. W artykule rozważam przyczyny rozpadu, a także analizuję dyskusję na ten temat wewnątrz OUN i podejmowane próby porozumienia. Szczególnie istotnym wątkiem jest konflikt o taktykę działania ukraińskich nacjonalistów na terenie II Rzeczypospolitej, który prześledziłam na przykładzie dwóch wydarzeń – napadu na pocztę w Gródku Jagiellońskim oraz zabójstwa Tadeusza Hołówki.
Uwolnić wolność. Teologia wolności według Josepha Ratzingera – Benedykta XVI
Authors: Góźdź Krzysztof
Published: July 2024

Wolność człowieka ma dzisiaj wiele imion. W różnych dziedzinach życia przejawia się jako wolność wyboru, wolność egzystencjalna, wolność prozopoiczna, wolność społeczno-polityczna oraz wolność religijna. Joseph Ratzinger – Benedykt XVI proponuje jeszcze inne rozumienie wolności człowieka. Polega ona na uznaniu swojej stworzoności, czyli ujęciu życia człowieka jako daru pochodzącego od Boga. Dlatego postuluje on „uwolnienie” takiej wolności, która w swej zależności od Stwórcy przybiera formę miłości. Prawda ta wyraża się w tryptyku: wolności samego Boga, wolności synostwa i wolności człowieka.
The Pastor as the Father of the Parish
Authors: Lipiec Dariusz
Published: July 2024

The aim of this article is to present the parson as a father. The necessity of being a father for particular parishioners and for the parish community results from the Church’s teaching. Fatherhood of a priest is based on the theological grounds mainly the patrylogical ones. It results from the inner relations of the Holy Trinity – of the Father with the Son and with the Holy Spirit as well as from the relations of the Father with people. The need for the realization of the parson’s service in the paternal way also results from the current pastoral conditions. These consist in the believers’ expectations that the parson should be in a personal relationship with them in a paternal way and their need to build Christian communities on the direct relationships between their particular members.
Disabled Persons in the Church: The Concept of Active Church and its Actors
Authors: Zielińska-Król Katarzyna
Published: July 2024

There are still a significant number of people with disabilities who remain beyond the Church’s evangelical reach, and there is still a large gap between able-bodied and disabled people in terms of participation in the community of the Church. The aim of this article is to answer the following questions: What is an active Church? Who should be the initiator of change, activity, and inclusion in the idea of an active Church? The article proposes an original concept of an active Church (KAK), which is an answer to the above questions. KAK was created on the basis of the experiences of surveyed people with disabilities and their caregivers (qualitative research) and ministers (quantitative research). KAK points to three entities responsible for the active participation of people with disabilities in the Church to meet the assumptions of experienced belonging.
Normy prawne i obyczajowe dotyczące małżeństwa w pismach asyryjskiego metropolity Mar Abdiszo (†1318)
Authors: Abdalla Michael , Wawrzyniak Sandra
Published: July 2024

Artykuł przedstawia analizę prac średniowiecznego uczonego asyryjskiego, metropolity Mar Abdiszo (†1318), dotyczących norm prawnych i obyczajowych w zakresie małżeństwa w Kościele asyryjskim. Mar Abdiszo był ostatnim z wielkich pisarzy asyryjskich, piszącym zarówno w języku syriackim, jak i arabskim, dlatego jego twórczość zasługuje na szczególną uwagę. Opisane przez metropolitę zagadnienia dotyczące małżeństwa zostały w roku jego śmierci zatwierdzone przez synod Kościoła asyryjskiego i poza nielicznymi modyfikacjami obowiązują do dziś w ramach prawa kanonicznego. Temat małżeństwa autor podejmuje całościowo. Po opisie znaczenia i ważności zaręczyn i narzeczeństwa oraz istoty małżeństwa omawia ich cele, wymienia przeszkody stojące przed zawarciem związku małżeńskiego oraz powody, które mogą doprowadzić do rozwodu. Interesującym aspektem badań jest odnotowanie, że jednożeństwo było charakterystycznym elementem kultury Asyryjczyków już w połowie III tysiąclecia p.n.e.
Renewable, Flexible, and Storage Capacities: Friends or Foes?
Authors: Peng Xiaoshan , Wu Owen Q. , Souza Gilvan C.
Published: July 2024

Problem definition: More than 99% of the new power generation capacity to be installed in the United States from 2023 to 2050 will be powered by wind, solar, and natural gas. Additionally, large-scale battery systems are planned to support power systems. It is paramount for policymakers and electric utilities to deepen the understanding of the operational and investment relations among renewable, flexible (natural gas-powered), and storage capacities. In this paper, we optimize both the joint operations and investment mix of these three types of resources, examining whether they act as investment substitutes or complements. Methodology/results: Using stochastic control theory, we identify and prove the structure of the optimal storage control policy, from which we determine various pairs of charging and discharging operations. We find that whether storage complements or substitutes other resources hinges on the operational pairs involved and whether executing these pairs is constrained by charging or discharging. Through extensive numerical analysis using data from a Florida utility, government agencies, and industry reports, we demonstrate how storage operations drive the investment relations among renewable, flexible, and storage capacities. Managerial implications: Storage and renewables substitute each other in meeting peak demand; storage complements renewables by storing surplus renewable output; renewables complement storage by compressing peak periods, facilitating peak shaving and displacement of flexible capacity. These substitution and complementary effects often coexist, and the dominant effect can alternate as costs change. A thorough understanding of these relations at both operational and investment levels empowers decision makers to optimize energy infrastructure investments and operations, thereby unlocking their full potential.

Funding: This research was supported in part by Lilly Endowment, Inc., through its support for the Indiana University Pervasive Technology Institute. This research was also supported by Kelley School of Business, Indiana University, and Haslam College of Business, University of Tennessee. O. Q. Wu thanks Grant Thornton for their generous support.

Supplemental Material: The online appendix is available at https://doi.org/10.1287/msom.2023.0068 .
Empowering Education: Unveiling The Transformative Potential of Pedagogical Competence for Educator and Learners
Authors: Bagea Ishak , Bagea Arfin , Bakar Abu
Published: July 2024

Paper writing aims to explain the empowering education unveiling the transformative potential of pedagogical competence for educator and learners. Pedagogics is a science that discusses education, namely the science of children's education. So pedagogic explains the ins and outs of children's education, pedagogic is a theory of children's education. Pedagogics as a science is needed by teachers. The task of the teacher is not only to teach to convey or transform knowledge to students at school, but the teacher has the task of developing the personality of his students in an integrated manner.
The teacher develops the child's mental attitude, develops the child's conscience or the child's heart so that the child will be sensitive to humanitarian issues, human dignity, as well as the teacher only develops children's skills, life skills in society so that he is able to face all the problems of his life.
Conclusion in writing papers: pedagogy competence is a set of knowledge, skills, and behaviors that must be possessed, lived and mastered by teachers or lecturers in carrying out professional duties.
This type of research uses qualitative research by means of researchers conducting observations, interviews and documentation with key informants and supporting informants, namely, teachers and students at the Muhammadiyah Kendari Private High School, and the novelty of the results of this research will be useful for the development of science, especially related educational sciences. how teachers and lecturers must master pedagogical competence, social competence, personality competence and social competence.
 Conclusion: pedagogical competence has a central role in shaping quality and relevant education. The transformative potential of pedagogical competence not only enriches students' learning experiences, but is also the key to the sustainability and success of the education system in the future. Therefore, continuous efforts in developing and strengthening pedagogical competence need to be implemented as a long-term investment to improve the quality of education.